CN111705081A - Construction and application of adenovirus carrying human RhoGDI3 gene shRNA - Google Patents
Construction and application of adenovirus carrying human RhoGDI3 gene shRNA Download PDFInfo
- Publication number
- CN111705081A CN111705081A CN202010498909.XA CN202010498909A CN111705081A CN 111705081 A CN111705081 A CN 111705081A CN 202010498909 A CN202010498909 A CN 202010498909A CN 111705081 A CN111705081 A CN 111705081A
- Authority
- CN
- China
- Prior art keywords
- shrna
- adenovirus
- rhogdi3
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a construction and application of an adenovirus carrying a humanized RhoGDI3 gene shRNA, belonging to the technical field of biological medicine. The adenovirus contains shRNA for inhibiting the expression of a human source RhoGDI3 gene, and the sequence of the shRNA is shown as SEQ ID NO.1 and SEQ ID NO. 2. The adenovirus of the invention can realize the in vivo knockout of RhoGDI3 gene, achieve the effect of inhibiting the hyperplasia of intima of blood vessels, and is used for preparing the medicine for treating vascular diseases.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to construction of an adenovirus carrying a humanized RhoGDI3 gene shRNA and application of the adenovirus in preparation of a drug for treating vascular remodeling diseases.
Background
Rho-specific guanylate dissociation inhibitor (RhoGDI) is critical for the homeostasis of Rho proteins and cross talk between family members. There are three subtypes of RhoGDI: RhoGDI1, RhoGDI2, RhoGDI3, which play important roles in a number of cell functions, such as cell proliferation and migration. RhoGDI1 (also known as RhoGDI α or ARHGDIA) is the most abundant of the most specific ones in this family and is expressed ubiquitously. RhoGDI2 (also known as RhoGDI β, Ly-GDI, D4-GDI or ARHGDIB) is usually highly expressed in hematopoietic cells, but is also found in other cells, such as cancer cells. RhoGDI3 (also known as RhoGDI gamma or ARHGDIG) is specifically expressed in lung, brain and testis. Many studies have shown that RhoGDI expression is significantly altered in a range of cancers.
The inventors found in previous studies that RhoGDI3 is significantly highly expressed during the proliferation of human platelet-derived growth factor BB (PDGF-BB) induced Vascular Smooth Muscle Cells (VSMCs), and thus it was considered that RhoGDI3 may be closely related to Vascular remodeling. Vascular remodeling is considered to be the pathophysiological basis for cardiovascular diseases (such as hypertension, atherosclerosis, and restenosis), and the shift of VSMCs from a contractile phenotype to a proliferative synthetic phenotype plays a key role in vascular development and remodeling. Currently, there is no effective RhoGDI3 inhibitor or drug that reduces its synthesis, so that the preparation of recombinant adenovirus can achieve the purpose of effective and stable knockout of RhoGDI3 in vitro and in vivo, and can be used for treating vascular diseases such as vascular intimal thickening or vascular restenosis.
Disclosure of Invention
The invention aims to provide a shRNA adenovirus carrying a human RhoGDI3 gene, which can realize the in vivo knockout of the RhoGDI3 gene, achieve the effect of inhibiting the hyperplasia of intimal vessels and can be used for treating vascular remodeling diseases.
In order to achieve the purpose, the invention adopts the following technical scheme:
a shRNA adenovirus carrying a human RhoGDI3 gene is characterized in that: the adenovirus contains shRNA for inhibiting the expression of a human source RhoGDI3 gene, and the sequence of the shRNA is shown as SEQ ID NO.1 and SEQ ID NO. 2.
The construction method of the adenovirus comprises the following steps:
step 1, designing and synthesizing shRNA shown by SEQ ID NO.1 and SEQ ID NO.2 aiming at a target gene RhoGDI 3;
step 2, annealing the synthesized shRNA, performing ligation reaction on the vector pAdM-shRNA-GFP which is subjected to enzyme digestion by BamH I and Hind III by using DNA ligase, transforming DH5 alpha competent bacteria, extracting a plasmid, and performing sequencing verification;
and 3, transfecting the virus vector successfully connected with the interference sequence to HEK293 cells to obtain the adenovirus.
The application of the adenovirus in preparing the medicine for treating vascular diseases.
Further, the vascular disease is intimal thickening or restenosis of the blood vessel.
The recombinant adenovirus prepared by the invention carries the shRNA sequence of RhoGDI3, can realize the purpose of effectively and stably knocking out the gene in vitro and in vivo, can selectively aim at the RhoGDI3 subtype, has no influence on the other two RhoGDI subtypes, thus not influencing the physiological functions of the two RhoGDI subtypes and greatly reducing the side effects generated by common inhibitors.
The recombinant adenovirus of the invention can be used for treating vascular diseases such as vascular intimal thickening or vascular restenosis and the like.
Drawings
FIG. 1 is a map of a hollow plasmid in example 1.
FIG. 2 shows the results of electrophoresis detection of the cleavage of the adenovirus vector in example 1.
FIG. 3 shows the results of the specific detection of adenovirus in example 1.
FIG. 4 is the results of the vascular HE staining in example 2.
Detailed Description
The following examples further illustrate the present invention but are not to be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples are in accordance with the conventional conditions in the art.
DMEM high-glucose medium was purchased from gibioc, cat #: c11965500BT
HEPES solution 1M was purchased from HyClone, cat #: SH30237.01
Penicillin-streptomycin solution (100 x) was purchased from petunia, cat #: c0222
Fetal bovine serum was purchased from Gibico, cat No.: 1122050
0.25% trypsin was purchased from HyClone, cat #: SH30042.01
10xPBS was purchased from bi yun sky, cat No.: ST476
DMSO was purchased from solarbo, cat #: d8372
Example 1
Construction of adenovirus
Firstly, selecting pAdM-shRNA-GFP as adenovirus vector
FIG. 1 is a schematic diagram of the adenovirus vector pAdM-shRNA-GFP and the key sites therein, the target fragment being inserted into the BamH I and Hind III sites.
Second, design of primers
Third, construction of adenovirus vector carrying human RhoGDI3 gene shRNA
1. The vector was digested, then the digestion was detected by electrophoresis on 1% agarose gel, and the vector was recovered using a gel recovery kit.
The enzyme digestion system is as follows:
components of reaction solution | Volume of |
Plasmid (1. mu.g/. mu.L) | 1μL |
10×Buffer | 3μL |
BamH I | 1μL |
Hind III | 1μL |
ddH2O | 24μL |
Total | 30μL |
Adding sample, mixing, and enzyme-cutting at 37 deg.C for 1-2h (without adding AP).
2. Annealing: the primers were then centrifuged instantaneously, and (nmol 10) μ L H was added to the dry primer powder2O, mother liquor diluted to 100. mu.M.
The annealing reaction system is as follows:
components of reaction solution | Volume of |
RhoGDI3_F | 1μL |
RhoGDI3_R | 1μL |
Buffer 3.1(NEB) | 3μL |
ddH2O | 25μL |
Total | 30μL |
Reaction procedure:
3. connecting: diluting the annealing product by 100 times, and connecting the annealing product with the enzyme-cut vector.
The linking system is as follows:
composition (I) | Volume of |
Diluted annealed product | 2μL |
Enzyme digestion vector | 2μL |
10×T4 Buffer | 1μL |
T4 DNA ligase (10U/. mu.L) | 1μL |
ddH2O | 4μL |
Total | 10μL |
Mixing, centrifuging instantly, and connecting at 22 deg.C for 2 h.
4. And (3) transformation: the ligation products were transformed into E.coli DH 5. alpha. competent cells and plated on correspondingly resistant LB plates for resistance selection.
The method comprises the following specific steps:
(1) taking prepared DH5a from-80 deg.C, placing in ice bath;
(2) after the DH5a competent cells were thawed, 1. mu.L of the ligation product was placed in 20. mu.L of DH5a competent cells, mixed well and left to stand in ice bath for 30 minutes;
(3) putting the centrifuge tube into a 42 ℃ water bath kettle for 40 seconds (without shaking the centrifuge tube), then quickly moving the centrifuge tube into an ice bath, and standing for 2 minutes;
(4) add 200. mu.L of sterile LB medium (without antibiotics) to the tubes, mix well and place in a shaker at 37 ℃ and 200rpm for 1 hour. Aims to express related resistance marker genes on plasmids and recover thalli;
(5) spreading into solid culture medium plate with corresponding resistance;
(6) incubated overnight in a 37 ℃ incubator.
5. And (4) extracting plasmid for sequencing verification after single colony culture.
The sequencing result verifies that the recombinant plasmid is successfully constructed.
Fourth, recombinant adenovirus package carrying human RhoGDI3 gene shRNA and preparation
1. Enzyme digestion
Enzyme digestion system:
composition of matter | Volume of |
Plasmid DNA | 20 μ L (about 2-3 μ g) |
10×buffer | 5μL |
dd H2O | 24.5μL |
Pac1 | 0.5μL |
Total volume | 50μL |
At 37 deg.C for 3 hr; 95 ℃ for 5min, 50. mu.L.
2.1% agarose gel electrophoresis detection, the electrophoresis shows two bands, one band is 3kb or about 5kb, and the other band is about 30 kb. As shown in fig. 2.
3. Transfection (transfection 6 well plate)
(1) Preparing Mix1 from 250 mu L DMEM and 8 mu L PEI, and standing for more than 5 min;
(2) preparing 250 mu L DMEM and the recombinant plasmid subjected to enzyme digestion into Mix 2;
(3) mixing Mix1 and Mix2, shaking and mixing evenly, centrifuging and standing for 30min (generally more than 30min so as to have enough time to form a DNA-PEI complex);
(4) laying 6-well plate HEK293 cells during standing, the number of the cells is about 0.3-0.5 × 106Per well;
(5) the mixture after standing was added dropwise to 6-well plate cells. Cross mixing and placing in CO2Culturing in an incubator.
4. Amplification and detoxification steps
(1) Blowing down the cells with CPE in the six-hole plate and the culture medium, adding the cells into a 10cm dish, shaking up, and placing the dish in CO2Culturing in an incubator for 2-3 days, and collecting toxin;
(2) collecting 10cm disc cells with CPE effect, moving the cells into a 15mL centrifuge tube by using an electric pipette gun, and making corresponding marks; 3500rpm, centrifuging for 7 min;
(3) after centrifugation, the tube was removed, the supernatant was decanted (the virus requiring amplification in large amounts was decanted into a fresh 15mL tube for use, stored at 4 ℃ for a short period of time, and at-80 ℃ for a long period of time), and the remainder was pipetted clean with a 200. mu.L gun. The precipitate was then redissolved with 1mL of 1x A195;
(4) continuously blowing and beating the precipitate by using A195 to ensure complete redissolution, then respectively sucking the precipitate into 1.5mL EP tubes, and making corresponding marks;
(5) putting the prepared EP tube into dry ice for freezing for 6-10min, then putting the tube into a dry thermostat, setting the temperature to 37.0 ℃, taking out the tube when a little ice blocks remain in the tube, reversing the tube by hand, uniformly mixing the tube and the tube, and repeatedly freezing and thawing for four times;
(6) after freezing and thawing, centrifuging for 2min at 12000g by using an EP tube;
(7) the supernatant was transferred to a two-dimensional code tube with a 1mL gun and then stored in a refrigerator at-80 ℃.
5. Bulk amplification and detoxification step
(1) The collected virus supernatant is evenly dripped into 10cm plates, evenly mixed and placed in CO2Culturing in incubator for 2-3 days, and collecting toxin.
(2) Collecting 10 disc cells with CPE effect, respectively transferring to a 50mL centrifuge tube by using an electric pipette, and marking correspondingly;
(3) centrifuging at 3500rpm for 7min, and collecting supernatant and cell precipitate respectively;
(4) adding NaCl and PEG8000 into the virus supernatant, shaking up once every 30min, shaking up three times, standing at 4 deg.C overnight. The cell pellet was stored at-80 ℃ for subsequent experiments.
6. Treatment before purification
(1) Viral supernatant treatment
1) Centrifuging the supernatant at 4 deg.C overnight at 3500g, 4 deg.C for 30 min;
2) centrifuging, removing supernatant, and collecting virus precipitate;
3) the virus pellet was resuspended in 2mL A195 and collected in a 15mL tube.
(2) Cell pellet treatment
1) The cell pellet was resuspended in 6mL A195, mixed well and freeze-thawed four times repeatedly. During freeze thawing, putting the sample in dry ice for freezing for 12-15 minutes, then taking the sample to a water bath kettle at 37 ℃ for melting for 2-3 minutes, and repeating the steps for four times;
2) after freezing and thawing, 3500g, 4 ℃, centrifuging for 30min, and respectively collecting supernatant and sediment (cell debris);
3) mixing the supernatant with the resuspended viral pellet; after resuspending the cell debris with 2mL of A195, 0.5mL of 5mol/L NaCl was added to a final concentration of 1 mol/L.
(3) Ultrasonic disruption of cells
1) Ultrasonically crushing the resuspended cell fragments for 3-4 times (AMPL value is 30%, 30 s/time, and the interval is 20-30s each time) until the liquid is not viscous;
2) after the ultrasonic treatment is finished, subpackaging the liquid into 2 EP tubes, and centrifuging at 12000rpm and 4 ℃ for 10 min;
3) after centrifugation, the cells were mixed with the virus supernatant and the cell pellet-treated sample.
7. Purification and concentration
(1) And (3) purification: iodixanol density gradient centrifugation
1) Preparing iodixanol with different concentrations according to a certain proportion;
2) taking a super-ionization tube, adding iodixanol with different concentrations layer by using an electric pipette, firstly adding 4.2mL of a 60% layer, then adding 5mL of a 40% layer, secondly adding 6mL of a 25% layer, and finally adding 9mL of a 15% layer;
3) adding the treated virus liquid to the uppermost layer;
4) and (4) carrying out ultra-high speed centrifugation at 48000rpm for 2 hours and 30 minutes, and before centrifugation, balancing the corresponding ultracentrifuge tube, wherein the error is controlled within 0.1 g.
(2) Concentrating
1) After centrifugation, puncturing the bottom of the ultrafiltration tube by using a needle, discarding the first 5mL, and collecting the 6mL to 10mL solutions to a 15mL tube;
2) the collected 5mL of liquid was diluted to a volume of 15mL with PBS + PF68 and then filtered through a 0.20 μm filter;
3) placing the filtered liquid in a 15mL ultrafiltration tube, centrifuging for 50min at 3500g, if the volume is not ideal, discarding the liquid to be removed, adding PBS + PF68 into the ultrafiltration tube for dilution, and centrifuging again, wherein the time can be determined according to the viscosity degree of the solution;
4) repeatedly blowing and beating the residual liquid in the ultrafiltration tube, sucking the liquid into a virus storage tube, and finally adding 5 xA 195 storage liquid until the final solubility of the storage liquid is 1x, wherein the name and the date are marked;
5) and (3) vortexing, shaking and uniformly mixing the collected viruses, centrifuging, and sucking 10 mu L of virus liquid for titer detection.
Fifthly, detecting titer and specificity of recombinant adenovirus
1. Adenovirus treatment to destroy the viral coat
Composition of matter | Volume of |
Virus liquid | 5μL |
Proteinase K (5 mug/muL) | 1μL |
Ultrapure water | 4μL |
The enzyme was inactivated by incubation at 37 ℃ for 30min and then heated to 95 ℃ for 5 min.
2. Centrifuging at 12000rpm for 2min, and collecting supernatant
3、QPCR
(1) Copy number of plasmid standard, 7 gradient dilution concentrations: 2.58E +12 vp/. mu.L, 2.58E +11 vp/. mu.L, 2.58E +10 vp/. mu.L, 2.58E +9 vp/. mu.L, 2.58E +8 vp/. mu.L, 2.58E +7 vp/. mu.L, and ultrapure water as a negative control.
(2) PCR reaction systems were prepared, and 20. mu.L of each sample was used.
Composition of matter | Volume of |
2X SYBRGreen buffer | 10μL |
F. R primer mixture | 0.8μL |
Ultrapure water | 7.2μL |
Viral samples or standards | 2μL |
The primer sequence is as follows:
F:GATCCGCCTGAAGGAAGGTGTTGATTATTC(SEQIDNO.3)
R:GGTGTTGATTATCTCTTGAATAATCAAC(SEQIDNO.4)
(3) performing a PCR reaction
5min at 95 ℃; 15sec at 95 ℃; 15sec at 60 ℃; 72 ℃ for 15 sec; 40 cycles
(4) Number of virus particles
Number of virus particles (one/mL) × 1000 relative to standard
4. Specificity detection
Taking out the product obtained in the step 3 | 1.5μL |
10 × Taq enzyme buffer | 2μL |
dNTP | 0.4μL |
Taq enzyme | 0.3μL |
DMSO | 1μL |
F, R primer mixture | 4μL |
Ultrapure water | 10.9μL |
The primer sequence is as follows:
F:GATCCGCCTGAAGGAAGGTGTTGATTATTC(SEQIDNO.3)
R:GGTGTTGATTATCTCTTGAATAATCAAC(SEQIDNO.4)
performing a PCR reaction program:
95℃4min;95℃30sec;64℃45sec;72℃1min 1cycles
95℃30sec;62℃45sec;72℃1min 2cycles
95℃30sec;60℃45sec;72℃1min 3cycles
95℃30sec;58℃45sec;72℃1min 26cycle
10min at 72 ℃; at 4 ℃ infinite
And (3) running glue, sweeping glue, comparing the sizes of the strips, diluting the PCR product of the universal primer and adding ultrapure water for 3 times for sequencing if the specific primer can not run out of the strips or the specific primer is absent, and comparing the sequences.
The electrophoresis result is shown in FIG. 3, and the size of the band after PCR of the universal primer of the target gene is correct.
Example 2
Recombinant shRhoGDI3 adenovirus for relieving vascular intimal hyperplasia vascular stenosis
Constructing a vascular stenosis model by an LCCA method.
Mice were anesthetized by intraperitoneal injection of 10% chloral hydrate (0.3mL/100g), a 1-1.5cm incision was made in the middle of the neck after hair removal, and the right common carotid artery was isolated and left untreated as a control. The left common carotid artery was then isolated and its distal end ligated with suture. The skin was sutured and then given normal feeding. After 14 days of molding, the experimental animals were anesthetized and sacrificed, the left common carotid artery was rapidly isolated, the blood vessels were washed with pre-cooled physiological saline, and stored in a refrigerator at-80 ℃.
2. Tail vein injection of 0.1mL virus solution (titer 1 × 10)10pfu)
3. The left carotid artery was taken and examined for intima/media ratio by HE staining.
HE staining procedure was as follows:
(1) cleaning separated common carotid artery after two weeks of molding with normal saline, sucking to dry with filter paper, storing a part of the common carotid artery in a refrigerator at-80 ℃, and fixing the rest in 4% paraformaldehyde;
(2) cutting a left and right carotid artery injury section of 0.5cm, carrying out OCT embedding, and carrying out frozen section by using a freezing microtome according to the thickness of 5 mu m;
(3) staining the OCT embedded section with hematoxylin staining solution for 5min, washing with double distilled water for 1min, differentiating with hydrochloric acid for 30s, soaking in double distilled water for 15min, and staining with eosin staining solution for 2 min;
(4) dehydrating the dyed slices with ethanol, and making the slices transparent with xylene;
(5) and (5) observing and photographing under a microscope.
As shown in FIG. 4, compared with the sham (sham) group, the vascular intima of mice in the LCCA group was significantly thickened and the luminal diameter was narrowed, and the vascular intimal hyperplasia in the recombinant shRhoGDI3 adenovirus treated group was significantly reduced and the luminal diameter was enlarged. The result shows that the knock-down of RhoGDI3 can significantly reduce intimal hyperplasia and vascular stenosis, and the recombinant shRhoGDI3 adenovirus can be used for treating cardiovascular diseases such as vascular restenosis.
Sequence listing
<110> university of southeast Tong
<120> construction of shRNA adenovirus carrying human RhoGDI3 gene and application thereof
<130>20200604
<160>4
<170>SIPOSequenceListing 1.0
<210>1
<211>64
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
gatccgcctg aaggaaggtg ttgattattc aagagataat caacaccttc cttcaggttt 60
ttta 64
<210>2
<211>64
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
agcttaaaaa acctgaagga aggtgttgat tatctcttga ataatcaaca ccttccttca 60
ggcg 64
<210>3
<211>30
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
gatccgcctg aaggaaggtg ttgattattc 30
<210>4
<211>28
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
ggtgttgatt atctcttgaa taatcaac 28
Claims (4)
1. A shRNA adenovirus carrying a human RhoGDI3 gene is characterized in that: the adenovirus contains shRNA for inhibiting the expression of a human source RhoGDI3 gene, and the sequence of the shRNA is shown as SEQ ID NO.1 and SEQ ID NO. 2.
2. The method for constructing an adenovirus according to claim 1, wherein: the method comprises the following steps:
step 1, designing and synthesizing shRNA shown by SEQ ID NO.1 and SEQ ID NO.2 aiming at a target gene RhoGDI 3;
step 2, annealing the synthesized shRNA, performing ligation reaction on the vector pAdM-shRNA-GFP which is subjected to enzyme digestion by BamH I and Hind III by using DNA ligase, transforming DH5 alpha competent bacteria, extracting a plasmid, and performing sequencing verification;
and 3, transfecting the virus vector successfully connected with the interference sequence to HEK293 cells to obtain the adenovirus.
3. Use of the adenovirus of claim 1 in the manufacture of a medicament for the treatment of a vascular disease.
4. Use according to claim 3, characterized in that: the vascular disease is intimal thickening or restenosis of the blood vessel.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010498909.XA CN111705081B (en) | 2020-06-04 | 2020-06-04 | Construction and application of adenovirus carrying human RhoGDI3 gene shRNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010498909.XA CN111705081B (en) | 2020-06-04 | 2020-06-04 | Construction and application of adenovirus carrying human RhoGDI3 gene shRNA |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111705081A true CN111705081A (en) | 2020-09-25 |
CN111705081B CN111705081B (en) | 2022-12-02 |
Family
ID=72538688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010498909.XA Active CN111705081B (en) | 2020-06-04 | 2020-06-04 | Construction and application of adenovirus carrying human RhoGDI3 gene shRNA |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111705081B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071846A2 (en) * | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
CN104195137A (en) * | 2014-08-11 | 2014-12-10 | 徐州医学院 | Six2 genetic expression-inhibiting shRNA, lentiviral expression vector and construction method of lentiviral expression vector |
CN107998130A (en) * | 2018-01-08 | 2018-05-08 | 四川大学华西医院 | Application of RhoGDI inhibitor in preparation of medicine for treating nasopharyngeal carcinoma |
-
2020
- 2020-06-04 CN CN202010498909.XA patent/CN111705081B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071846A2 (en) * | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
CN104195137A (en) * | 2014-08-11 | 2014-12-10 | 徐州医学院 | Six2 genetic expression-inhibiting shRNA, lentiviral expression vector and construction method of lentiviral expression vector |
CN107998130A (en) * | 2018-01-08 | 2018-05-08 | 四川大学华西医院 | Application of RhoGDI inhibitor in preparation of medicine for treating nasopharyngeal carcinoma |
Non-Patent Citations (2)
Title |
---|
FAN DAI ET AL.,: "RhoGDI stability is regulated by SUMOylation and ubiquitination via the AT1 receptor and participates in Ang II-induced smooth muscle proliferation and vascular remodeling", 《ATHEROSCLEROSIS》 * |
刘姿麟等: "大鼠shRNA-Slfn1 重组腺病毒载体的构建与鉴定", 《贵州医科大学学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111705081B (en) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109182278B (en) | Seikaga valley virus strain and application thereof | |
CN107586759B (en) | Construction method and application of recombinant Newcastle disease virus | |
CN110093320B (en) | Swine sai-Ka virus GD-SVA-2018 strain and application thereof | |
CN107164409B (en) | Canine distemper virus sensitive cell line SLAM-MDCK and construction method and application thereof | |
CN105087645A (en) | Building and application of M protein three-amino acid site-mutated vesicular stomatitis virus (VSV) carrier for pigs | |
CN111718956B (en) | Preparation method and application of chicken-derived TRIM25 gene recombinant fluorescent expression plasmid | |
CN110205308A (en) | It is a kind of express HA gene recombinant herpesvirus of turkeys and its application | |
CN113244412A (en) | Medicine for treating hyperuricemia or gout based on mRNA dosage form and preparation method thereof | |
CN113559134A (en) | Medicine for treating tumor | |
CN111705081B (en) | Construction and application of adenovirus carrying human RhoGDI3 gene shRNA | |
CN110129318A (en) | Long-chain non-coding RNA PRALR and its expression plasmid and purposes | |
CN110129319B (en) | siRNA of PRALR and application thereof | |
CN115141273B (en) | Monoclonal antibody of feline calicivirus and application thereof | |
CN114213505B (en) | Adeno-associated virus mutant suitable for specifically infecting U87-MG cells | |
CN108707625A (en) | Mir-124 and HER2-shRNA double gene expression boxes viral vectors, construction method, virus, application | |
CN110699328B (en) | B-type porcine enterovirus and application thereof | |
CN105420275A (en) | Method for preparing exogenous functional gene targeted integration human neural stem cells | |
CN110863011A (en) | Construction method and application of plasmid and adenovirus for interfering expression of pig CRTC3 | |
CN113122538A (en) | shRNA expressed by targeted knockdown Rip3 gene, recombinant vector and application thereof | |
CN113528568A (en) | Infectious clone of jute vein yellow virus and construction method thereof | |
CN110904056A (en) | Infectious bronchitis virus rH120-YZS1 delta 5a and construction method and application thereof | |
CN111647656A (en) | Application of mir-29a gene in detection of liver cancer and liver fibrosis and construction method of conditional knock-in mouse of gene | |
CN111471715A (en) | Adenovirus vector and construction method and application thereof | |
CN111840327B (en) | Mesenchymal stem cell preparation for treating diabetic foot and application thereof | |
CN111228292B (en) | Application of human TPT1/TCTP gene in preparation of antitumor drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |